HomeNews News Delhi High Court quashes Cipla's appeal, can't market generics of Novartis' Onbrez Delhi High Court quashes Cipla's appeal, can't market generics of Novartis' Onbrez

Read more interesting news from around the globe with Wealth Doctor App

Google Play
 
Delhi High Court quashes Cipla's appeal, can't market generics of Novartis' Onbrez

Delhi High Court quashes Cipla's appeal, can't market generics of Novartis' Onbrez

Thursday, March 9, 2017, 5:35 PM

Onbrez, Novartis' brand of the chemical drug indacaterol, is used to treat chronic obstructive pulmonary disease (COPD). Indian drug maker Lupin Ltd imports and markets Onbrez here through a 2012 agreement with Novartis. Justices Badar Durrez Ahmed and Sanjeev Sachdeva on Thursday dismissed Cipla's appeal to an earlier ruling by the Delhi High Court on several grounds.
Read More

Learn to Save, Spend, Invest & Borrow Wisely with our Youtube Channel

Love Beyond Death Get It now!